AREG and cancer: Pathological diagnoses revealed cancer occurrence rates of 16.7%, 100%, 66.7%, 50% and 50% in the wild-type (WT), CES-SV40 untreated, anti-AREG, FK866, and anti-AREG + FK866 groups, respectively (Fig. 8d).